As the amount of raw data generated by the MiSeq continues to grow we are starting to run into situations where even this "Benchtop" sequencer produces more data than is needed (or wanted) for a de novo genome assembly of things like bacteria and fungi, even with the Micro and Nano options. If I am going to do a de novo assembly offline I can simply downsample the data myself. But what if I want to use the built in MiSeq Reporter de novo assembly pipeline? Is there any way to configure it to only use a portion of the raw data for assembly?
Unconfigured Ad
Collapse
X
-
Currently the default assembly pipeline in the MiSeq can only handle 550Mb of sequence. You can decrease it by playing with the config files in MSR. You can read the MSR Theory of Operations document available on the Illumina website.
However, it seems strange to be throwing perfectly good reads away. Have you considered multiplexing more samples into the run so you generate more useful data?
-
-
Thanks for the info. Regarding multiplexing, yes that would be ideal, but as a core we have to take what researchers send us. Sometimes all they have is one sample.Originally posted by kcchan View PostCurrently the default assembly pipeline in the MiSeq can only handle 550Mb of sequence. You can decrease it by playing with the config files in MSR. You can read the MSR Theory of Operations document available on the Illumina website.
However, it seems strange to be throwing perfectly good reads away. Have you considered multiplexing more samples into the run so you generate more useful data?
Comment
-
-
MiSeq reporter v.2.1.43 was released just last week so it may be a new feature or an undocumented one Illumina wants people to generally stay away from.Originally posted by genbio64 View PostIs this feature new in the last software update? Illumina had told us there was virtually no flexibility when it came to the downstream pipelines through MSR.
Comment
-
-
It's definitely good practice not to mess with the default analysis settings. Changing the settings will affect all future analysis, so know what you're doing before playing with the config files and revert them back if the next person needs the default settings. Most of the time I find it easier to do the downstream analysis myself and not on the instrument.
Comment
-
-
Can I ask why you would even want Reporter to do de novo assembly? Unless things have changed with the newest version, Reporter (and Basespace) does no trimming or quality discrimination during its assembly, and I can't remember if it properly handles paired data. Every assembly done using Reporter that I've seen looks worthless compared to one's that I've done using Velvet on my own.
I guess if people are just sending you samples to sequence and intend to assemble it themselves, and you give them the assembly that Reporter spits out as a "bonus" along with the raw data then there's no real harm. But I think relying solely on an assembly done using Reporter or Basespace is pretty sloppy.
My opinion only of course though.
Comment
-
Latest Articles
Collapse
-
by SEQadmin2
Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.
The systematic characterization of the human proteome has...-
Channel: Articles
Today, 11:48 AM -
-
by SEQadmin2
Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
...-
Channel: Articles
07-09-2026, 11:10 AM -
-
by SEQadmin2
Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.
There is no single reason why many patients don’t respond to treatment as expected. Cancer is...-
Channel: Articles
07-08-2026, 05:17 AM -
ad_right_rmr
Collapse
News
Collapse
| Topics | Statistics | Last Post | ||
|---|---|---|---|---|
|
Started by SEQadmin2, Today, 11:10 AM
|
0 responses
8 views
0 reactions
|
Last Post
by SEQadmin2
Today, 11:10 AM
|
||
|
Started by SEQadmin2, 07-13-2026, 10:26 AM
|
0 responses
30 views
0 reactions
|
Last Post
by SEQadmin2
07-13-2026, 10:26 AM
|
||
|
Started by SEQadmin2, 07-09-2026, 10:04 AM
|
0 responses
39 views
0 reactions
|
Last Post
by SEQadmin2
07-09-2026, 10:04 AM
|
||
|
Started by SEQadmin2, 07-08-2026, 10:08 AM
|
0 responses
25 views
0 reactions
|
Last Post
by SEQadmin2
07-08-2026, 10:08 AM
|
Comment